May 16th, 2021 SAN DIEGO, Nov. 11, 2020 /PRNewswire/ --InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of...
Read ArticleMay 8th, 2021[gallery] This coming Friday will be the Chondrosarcoma Foundation’s first anniversary. Last year, on May 14, 2020 during the beginning of the pandemic, we launched the Chondrosarcoma Foundation by bringing CS Foundation web site on-line. My...
Read ArticleMay 7th, 2021November 13, 2020 Dylann Cohn-Emery Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in...
Read ArticleMay 7th, 2021Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year
Read ArticleApril 30th, 2021 Elena Cojocaru, Christopher Wilding, Bodil Engelman, Paul Huang & Robin L. Jones Current Molecular Biology Reports volume 6, pages1–9(2020)Cite this article Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? |...
Read ArticleApril 30th, 2021Abstract Dioxins are ubiquitous and persistent environmental contaminants whose background levels are still reason for concern. There is mounting evidence from both epidemiological and experimental studies that paternal exposure to the most potent...
Read ArticleApril 30th, 2021Sebastien passed away July 14, 2020 from dedifferentiated chondrosarcoma. This narrative was written and submitted by his sister Stephanie Desjardins. In April 2019, my brother was diagnosed with a chondrosarcoma of chest wall on the right side...
Read ArticleApril 29th, 2021Empowering Patients: Speak Up For Your Health Tuesday, May 11, 2021 at 12:00 PM ET Please consider registering to a special information session where our panel of experts will discuss the importance of advocating for patient care and treatment....
Read Article